Market Overview

The global genome editing market is witnessing an extraordinary growth phase, underpinned by scientific breakthroughs, mounting disease burden, and expanding commercial applications. According to The Insight Partners, the market was valued at US$ 5,199.40 million in 2021 and is projected to reach US$ 16,986.69 million by 2028, growing at a compelling CAGR of 18.4% during the 2022–2028 forecast period.

Genome editing — the precise insertion, deletion, or replacement of DNA sequences using molecular tools is reshaping therapeutic landscapes across oncology, rare genetic diseases, drug discovery, and agricultural biotechnology. As technologies mature and clinical pipelines deepen, segmentation across technology, application, end user, and geography reveals where the most powerful growth opportunities lie.

📥 Download Sample PDF Report  https://www.theinsightpartners.com/sample/TIPHE100000853

Segmentation Analysis: Where the Market Is Growing

By Technology CRISPR Leads with Highest CAGR

The technology segment is divided into CRISPR, TALEN, Antisense, and other emerging platforms. CRISPR/Cas9 dominates, holding the largest market share in 2021 and expected to register the highest CAGR through 2028. Its supremacy stems from being faster, cheaper, and significantly more accurate than earlier gene-editing methodologies. CRISPR's ability to target virtually any genomic sequence with programmable precision makes it the preferred tool across both research and clinical applications.

The CRISPR-Cas9 system creates site-specific double-stranded DNA breaks repaired through either nonhomologous end joining or homologous recombination, enabling targeted mutations with unmatched efficiency. The CRISPR-LNP system combining a messenger RNA encoding the Cas9 enzyme with lipid nanoparticle delivery is further advancing treatment of hereditary neurological disorders such as fragile X syndrome and Down syndrome. AI integration into CRISPR design is an accelerating trend, with platforms like Microsoft Azure being deployed to optimize gene therapy vector development.

TALEN (Transcription Activator-Like Effector Nucleases) and antisense technologies continue to serve specialized applications where CRISPR's versatility is less suitable, contributing meaningfully to the overall technology mix.

By Application Cell Line Engineering Dominates

Application-based segmentation includes Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery, and others. The cell line engineering segment held the largest share in 2021 and is projected to grow at the fastest CAGR through 2028, driven by its critical role in understanding disease biology, developing recombinant proteins, and producing industrial and commercial biologics.

Cell line engineering enables vaccine development, drug cytotoxicity testing, antibody production, gene function studies, and artificial tissue synthesis. Its advantages cost-effectiveness, unlimited material supply, ethical acceptability compared to animal tissues make it central to modern pharmaceutical R&D. Companies such as Horizon Discovery, Thermo Fisher Scientific, Lonza, and Merck KGaA are key suppliers of cell line engineering products and services.

Drug discovery is an adjacent high-growth application. CRISPR-based target identification and validation tools are compressing R&D timelines significantly, making gene editing indispensable to pharmaceutical pipeline development. Diagnostic applications are also expanding as molecular diagnostic tools incorporate genome editing principles for higher precision and sensitivity.

By End User Pharma and Biotech at the Forefront

End users are segmented into Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Clinical Research Organizations (CROs). Pharma and biotech companies held the dominant share in 2021 and are expected to maintain the fastest CAGR throughout the forecast period.

This dominance is fueled by escalating investment in gene-based therapy pipelines, high-value partnerships, and FDA-supported regulatory pathways. Eli Lilly's collaboration with Precision BioSciences a deal structured to generate up to USD 2.7 billion using the ARCUS genome editing platform exemplifies the scale of commercial commitment. The FDA's 2021 approval of Lumakras (Sotorasib) for KRAS G12C-mutant non-small cell lung cancer further validates the regulatory momentum supporting commercial genomics.

Academic and research institutes remain vital innovation engines, particularly in early-stage CRISPR research, while CROs are increasingly incorporating genome editing services into their outsourced R&D offerings.

By Geography North America Leads, Asia Pacific Surges

North America is the largest regional market, driven by the United States' mature biopharmaceutical sector, strong NIH and government funding, active clinical trial ecosystems, and FDA's supportive stance on gene therapies. The high prevalence of cystic fibrosis affecting 1 in 2,500 to 3,500 white newborns in the US and other genetic disorders sustains strong domestic demand.

Asia Pacific is the fastest-growing regional market, with China, India, Japan, and Australia driving adoption through rising healthcare investment, expanding genetic disorder diagnoses, and growing clinical research activity. Europe maintains a robust market position, anchored by pharmaceutical hubs in Germany, the UK, and France. The Middle East & Africa and South & Central America segments are emerging markets with increasing adoption for genetic disorder treatment and agricultural genome applications.

Top Market Players

The competitive landscape features global leaders and specialized innovators shaping the market's direction:

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Lonza
• Horizon Discovery Group plc.
• Integrated DNA Technologies (IDT)  launched rhAmpSeq CRISPR Analysis System (Nov 2021)
• GenScript
• New England Biolabs  acquired Fluorogenics Limited (May 2021)
• Eurofins Scientific  acquired Genetic Lab (G Lab) in Japan (Dec 2021)
• CRISPR Therapeutics
• Editas Medicine  received FDA IND clearance for EDIT-301 for beta thalassemia (Dec 2021)

Related Riport:   genome editing market size

Contact Us

• US: +1-646-491-9876
• UK: +44-20-8125-4005
• Email: sales@theinsightpartners.com
• Website: www.theinsightpartners.com

Also Available in :